# SAB Biotherapeutics (SABS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SABS
## Company Profile
- Ticker: SABS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 3.8 USD
- Market cap: 266095047.12 USD
- Last updated: 2026-08-12
## Business Overview
### Fully Human Polyclonal Antibodies
SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies.
### SAB-142
SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes.
### SAFEGUARD
The registrational Phase 2b SAFEGUARD study enrolls children and adults within 100 days of Stage 3 type 1 diabetes diagnosis.
## Why The Stock Is Moving

As of Aug 12, 2026, SABS closed up 1.06% at $3.80. No new same-company headline was identified in the current news window.

## Future Catalysts

- SAFEGUARD enrollment is expected to complete by year-end 2026.
- Topline SAFEGUARD data are expected in the second half of 2027.

## Drug Assets

- SAB-142

## Recent News
- 2026-08-06 11:30 EST — [SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/SABS/sab-bio-reports-q2-2026-financial-results-and-provides-business-highlights-596e64d5) — Source: SAB Biotherapeutics
- 2026-07-30 12:30 EST — [SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET](https://biopharmsignal.com/news/SABS/sab-bio-to-host-second-quarter-2026-financial-results-conference-call-and-webcas-99a1b001) — Source: SAB Biotherapeutics
- 2026-07-07 12:00 EST — [Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes](https://biopharmsignal.com/news/SABS/breakthrough-t1d-awards-grant-to-support-prise-hatg-study-of-sab-142-in-stage-3--2892a9e2) — Source: SAB Biotherapeutics
- 2026-05-29 12:00 EST — [SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting](https://biopharmsignal.com/news/SABS/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-association-s-2026-scientific-sessions-and-focis-2026-annual-meeting) — Source: SAB Biotherapeutics
- 2026-05-12 11:30 EST — [SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/SABS/sab-bio-reports-q1-2026-financial-results-and-recent-business-highlights) — Source: SAB Biotherapeutics